metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Building a culture of scientific integrity among the academic and research commu...
Información de la revista
Vol. 27. Núm. 1.
(enero - febrero 2022)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 27. Núm. 1.
(enero - febrero 2022)
Editorial
Open Access
Building a culture of scientific integrity among the academic and research communities of Latin America
Visitas
752
Alexis Jose-Abrego, Arturo Panduro
Autor para correspondencia
biomomed@cencar.udg.mx

Corresponding author: Arturo Panduro, MD., PhD., FAASLD, Department of Genomic Medicine in Hepatology, Civil Hospital of Guadalajara, “Fray Antonio Alcalde” and Health Sciences Center, University of Guadalajara. Calle Hospital # 278, Col. El Retiro, 44280, Guadalajara, Jalisco, Mexico. Tel: (52) 33 36147743.
Department of Genomic Medicine in Hepatology, Civil Hospital of Guadalajara, “Fray Antonio Alcalde” and Health Sciences Center, University of Guadalajara, Guadalajara, Jalisco, Mexico
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Texto completo

Making science is not a straight road, nor is it always about publishing positive results or glorious findings. Helen Wilkes from the Centre for Higher Education Research and Scholarship, Imperial College London, used the metaphoric illustration of the “scientific iceberg” [1] to show that at the tip are the apparent successes of science, but at the bottom, we find challenging situations such as low salary, precarious laboratory infrastructure, funding cuts for research institutions and universities, parasitism of private associations over funds destined for research, political manipulation of scientific information, and above all the strong influence of funders on speakers, researchers, institutions, publishers, and medical or scientific societies [2]. Unfortunately, these negative traits are more frequent in low and middle-income countries, including those of Latin America, where academics and researchers struggle against them on a daily basis [3]. In general, the lack of national scientific culture, limited interest in postgraduate research training, low governmental investment in research and technology, and few regional funding agencies are some inconveniences that jeopardize building a solid culture of scientific integrity [4,5].

In contrast, the United States Government has tackled this important aspect through the "Federal Scientific Integrity Policies" 6, while European academies have developed "The European Code of Conduct for Research Integrity" 7. Other countries share this initiative, such as the United Kingdom, founded the "UK Research Integrity Office." Similarly, Japan and Canada have published their policy about ethics and preservation of science [8,9]. Although these initiatives have not yet been widely replicated in Latin America, the efforts of some countries are significant; for instance, the Interdisciplinary Center for Studies on Bioethics (CIEB) of the University of Chile is dedicated to training Latin American professionals in responsible conduct of research (RCR) [10].

Building scientific integrity involves multiple issues such as core values, appropriate use of research funds, conducting research under ethical guidelines and with social responsibility, avoiding conflicts of interest, and preventing research misconduct [6–9]. Researchers, mentors, junior researchers, and science administrators must regulate their direct or indirect scientific activities under fundamental principles, such as Honesty, Reliability, Respect, and Accountability [6,7].

Notably, one controversial topic is managing conflicts of interest and specifically regarding the relationships with the pharmaceutical companies. In the last decades, Latin America has become an attractive venue for the pharmaceutical industry to produce medicines, conduct clinical trials, and market new drugs [11]. Conflict of interest may occur if medical professionals who participate in these multi-center and sometimes multi-national clinical trials or prescribe certain drug brands are later invited as speakers by medical societies and associations without presenting a disclosure or conflict of interest statement. Therefore, as part of the warranted scientific integrity, keynote or plenary speakers should always declare their relationship (research, consulting, or speaker) with companies in platform presentations, scientific articles, and books [12,13].

In medicine, building a culture of scientific integrity would bring many benefits, particularly for making clinical practice guidelines (CPG). In this sense, it is quite common in Latin America that purposefully trained clinicians are sometimes invited as speakers at medical meetings to talk about the growing knowledge even though they are not scientists who publish in the field. This action leads to only echoing the evidenced-based medicine taken from other regions and populations and reproducing foreign guidelines without generating our own research-based evidence. For this reason, we have proposed that the CPG in the field of Hepatology for the Latin American countries contain as much regional published scientific evidence as possible [14]. Obviously, this requires that science education be cultivated since childhood so that graduate students can develop their creativity, critical thinking, problem-solving, and teamwork [15,16] to do sound science and propose new theories based on the features of the Latin American populations.

Furthermore, a scientific environment free from political or company pressure will allow better cross-sectional, follow-up, clinical, or cohort studies focused on prevention models rather than promoting medical treatment with drugs (promoted by the pharmaceutical companies) [17]. The findings of these studies could be analyzed and discussed by regional medical-scientific academies. This scientific evidence will help health professionals make sound clinical decisions, choose the best treatment strategies, introduce new technologies for diagnosis, and improve patients' quality of life. Finally, strengthening medical societies under a free scientific culture will allow countries to feel prepared to face future challenges and achieve excellence in medical practice. New initiatives are warranted to create research integrity policies and agencies throughout Latin America at all levels of responsibility.

References
[1]
Imperial College London. The scientific iceberg. 2019. Available at: https://blogs.imperial.ac.uk/education-research/2019/02/12/the-scientific-iceberg/
[2]
Sheldon Krimsky. Combatting the Funding Effect in Science: What's Beyond Transparency? vol 21 Stanford Law & Policy Review 81. 2010. Available at: https://law.stanford.edu/publications/combatting-funding-effect-science-whats-beyond-transparency/
[3]
M Neil, C Saenz.
Advancing research ethics systems in Latin America and the Caribbean: a path for other LMICs?.
Lancet Glob Health, 8 (2020), pp. e23-e24
[4]
DR Ciocca, G. Delgado.
The reality of scientific research in Latin America; an insider's perspective.
Cell Stress Chaperones, 22 (2017), pp. 847-852
[5]
Red Latinoamericana de Cultura Científica. Available at: https://redlcc.org/about/
[6]
EU Congressional Research Service. Federal Scientific Integrity Policies: A Primer. 2021. Available from: https://crsreports.congress.gov/product/details?prodcode=R46614
[7]
ALL European academies. The European Code of Conduct for Research Integrity. 2017. Available from: https://www.allea.org/wp-content/uploads/2017/05/ALLEA-European-Code-of-Conduct-for-Research-Integrity-2017.pdf
[8]
Japan Society for the promotion of science. Research-Ethics education: Research Integrity. 2015. Available from: https://www.jsps.go.jp/english/e-kousei/ethics.html
[9]
Government of Canada. Research and scientific integrity policy. 2018. Available at: https://nrc.canada.ca/en/corporate/values-ethics/research-scientific-integrity-policy
[10]
E Rodríguez, F. Lolas.
The topic of research integrity in Latin America.
Bioethikos, 5 (2011), pp. 362-368
[11]
JL. Valverde.
Latin American pharmaceutical overview.
Pharmaceuticals, Policy and Law, 16 (2014), pp. 179-206
[12]
The University of Texas System.
Procedure for managing conflicts of interest.
[13]
H Rivera, A. Panduro.
Financial and other competing interests: be aware.
Ann Hepatol, 17 (2018), pp. 897-898
[14]
A Panduro, S. Roman.
Advancements in genomic medicine and the need for updated regional clinical practice guidelines in the field of hepatology.
Ann Hepatol, 19 (2020), pp. 1-2
[15]
C Murphy, G Martínez, M Aksela, G Bergman, M Jones, P Léna, et al.
A snapshot of Climate Change Education Initiatives in Europe. Initial findings and implications for future Climate Change Education.
All European Academies Report, 1 (2020), pp. 1-21
[16]
G. Bosch.
Train PhD students to be thinkers not just specialists.
[17]
A Panduro, C Tiribelli, NC Chávez-Tapia, M Arrese, M. Uribe.
Renovation of Annals of Hepatology's Scientific Scope: Towards Preventing Rather Than Treating End-Stage Liver Disease.
Ann Hepatol, 17 (2018), pp. 539-540
Copyright © 2022. Elsevier Ltd. All rights reserved
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2022.100682
No mostrar más